Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence